Patent · US Active

5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoMethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2 as NK1 receptor antagonists

US8344005B2 · kind B2 · utility

3Cited by

0References

5Claims

0Family size

Assignee

Glaxo Wellcome Manufacturing Pte Ltd · SG

Inventors

Giuseppe Alvaro · Stevenage, GB
Agostino Marasco · Verona, IT

Key dates

Filing date	May 12, 2009
Grant date	Jan 1, 2013
Priority date	—
Expiry date	Dec 9, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is C1-4 alkyluseful in the treatment of diseases and conditions for which antagonism of NK1 receptor is beneficial.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.